HomeAI · summaries
Storia in 4 fonti
PCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterol
Genetic PCSK9 inhibition via base editing appeared safe and demonstrated dose-dependent, durable reductions in PCSK9 and LDL cholesterol, researchers reported.At the highest dose, VERVE-102 (Verve Therapeutics) was associated with an up to 88% reduction in PCSK9 and a 62% reduction in LDL, and could represent a single-dose, lifelong therapeutic to prevent atherosclerotic CVD in people with
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
spectator.com
Gene-editing drugs are opening a new frontier in medicine
Medicines that we take only a few times and which permanently alter the trajectory of our lives for the better, are on the way.
- ·
medpagetoday.com
So Far, So Good for PCSK9-Targeting Gene Therapy in Hypercholesterolemia
Tweaked lipid nanoparticle delivery system showed early safety
- ·
arstechnica.com
Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial
The interim Phase I trial data was only from 35 people, but results look good so far.
- ·
One dose of gene-editing drug cut bad cholesterol 62% for months in small trial
The interim Phase I trial data was only from 35 people, but results look good so far.
- ·
healio.com
PCSK9 inhibition via base editing lowers LDL in patients with genetic high cholesterol
Genetic PCSK9 inhibition via base editing appeared safe and demonstrated dose-dependent, durable reductions in PCSK9 and LDL cholesterol, researchers reported.At the highest dose,…